Gemtuzumab ozogamicin for <i>de novo</i> acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial

Lambert, Juliette; Pautas, Cécile; Terré, Christine; Raffoux, Emmanuel; Turlure, Pascal; Caillot, Denis; Legrand, Ollivier; Thomas, Xavier; Gardin, Claude; Gogat-Marchant, Karïn; D. Rubin, Stephen; Benner, Rebecca; Bousset, Pierre; Preudhomme, Claude; Chevret, Sylvie; Dombret, Hervé; Castaigné, Sylvie

doi:10.3324/haematol.2018.188888

Public

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial

Published in Haematologica • Aug 3, 2018

Authors:

Juliette Lambert

Cécile Pautas

Christine Terré

Abstract

The randomized, phase III ALFA-0701 trial showed that a reduced and fractionated dose of gemtuzumab ozogamicin added to standard front-line chemotherapy significantly improves event-free survival (EFS) in adults with de novo acute myeloid leukemia (AML). Here we report an independent review of EFS, ...

Subject

Gemtuzumab ozogamicin

Medicine

Cytarabine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!